TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC

Pharmacy Times® interviewed Shirish Gadgeel, MD, chief of the Division of Hematology/Oncology at Henry Ford Cancer Institute, on a session at the European Society for Medical Oncology Congress 2024 in Barcelona, Spain, discussing an integrated analysis of the regional TRUST-I study (NCT04395677) and global TRUST-II study (NCT04919811). The studies looked at the efficacy and safety of taletrectinib (AB-106; AnHeart Therapeutics) in patients with ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC). The analysis showed that taletrectinib elicited high and durable overall response rates with favorable tolerability in the treatment of ROS1+ NSCLC.

Pharmacy Times: Can you discuss the combined analysis of the TRUST-I and TRUST-II trial results?

Image Credit: © mi_viri - stock.adobe.com

Shirish Gadgeel, MD: So, there were data presented—and actually, what was presented about talatrectinib was a combined analysis of TRUST-I and TRUST-II—and I think the most sort of pleasantly surprising data from that combined analysis was that the median progression-free survival exceeded 40 months, coming up to close to 4 years. I think in [NSCLC] in the advanced stage, that is quite remarkable when you compare it to other datasets from other subsets of [NSCLC]. So, I think that the biggest, [most] impressive data that was presented of that combined analysis. In addition, the tolerability of the drug seems to be fairly good. I don't have personal experience with the drug, but the data that was presented [shows that] the drug appears to be fairly well tolerated. And I think that this could be a very good option for us for patients if this drug gets FDA approved.